Healthcare [ 7/13 ] | Biotechnology [ 82/163 ]
NASDAQ | Common Stock
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland.
The company focuses on the discovery of G-protein coupled receptors and enzymes.
Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.
Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The Charcot"Marie"Tooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A.
The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jun 6, 24 | -4.06 Decreased by -194.01% | -0.03 Decreased by -13.03 K% |
| Nov 13, 23 | -4.60 Decreased by -5.01 K% | -0.03 Decreased by -14.79 K% |
| Aug 10, 23 | -0.04 Increased by +96.64% | -0.04 |
| May 11, 23 | -0.27 Increased by +70.62% | -0.05 Decreased by -420.16% |
| Mar 30, 23 | -1.38 Decreased by -69.30% | -0.05 Decreased by -2.57 K% |
| Nov 11, 22 | -0.09 Increased by +87.55% | -0.09 |
| Aug 18, 22 | -1.19 Decreased by -28.47% | -0.14 Decreased by -779.53% |
| May 5, 22 | -0.91 Decreased by -73.82% | -0.52 Decreased by -76.95% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 153.45 K Decreased by -69.36% | -2.86 M Decreased by -18.68% | Decreased by -1.86 K% Decreased by -287.39% |
| Dec 31, 23 | 153.45 K Decreased by -74.10% | -2.86 M Increased by +21.76% | Decreased by -1.86 K% Decreased by -202.04% |
| Sep 30, 23 | 327.73 K Decreased by -19.95% | -2.62 M Increased by +36.29% | Decreased by -798.54% Increased by +20.41% |
| Jun 30, 23 | 630.88 K Increased by +244.08% | -2.68 M Increased by +62.95% | Decreased by -424.04% Increased by +89.23% |
| Mar 31, 23 | 500.89 K Increased by +111.14% | -2.41 M Increased by +58.67% | Decreased by -480.58% Increased by +80.42% |
| Dec 31, 22 | 592.43 K Increased by +49.04% | -3.65 M Increased by +17.46% | Decreased by -616.38% Increased by +44.62% |
| Sep 30, 22 | 409.42 K Decreased by -39.97% | -4.11 M Decreased by -14.16% | Decreased by -1.00 K% Decreased by -90.16% |
| Jun 30, 22 | 183.35 K Decreased by -81.53% | -7.22 M Decreased by -53.97% | Decreased by -3.94 K% Decreased by -733.50% |